As I reflect on 2025, I feel a deep sense of pride, humility, and renewed commitment. This year reminded all of us at TrueMed why our mission matters. Around the world, patients continued to face an unprecedented rise in counterfeit medicines, and the need for rapid, reliable, and accessible authentication reached a new level of urgency.
Rising to a Global Counterfeit Crisis
2025 brought extraordinary clarity to the scale and sophistication of counterfeit drug operations. Month after month, our Counterfeit Drug News Roundups documented a pattern that spanned continents and therapeutic areas.
Large seizures of falsified cancer drugs, antibiotics, and allergy medications took place in India and Southeast Asia early in the year. As demand for certain products intensified, global markets saw increasing volumes of fake GLP-1 treatments, unsafe injectables, falsified Botox in Australia, and oncology medicines containing little or no active ingredients. These were not distant stories. They were reminders that every incident represents patients whose health was placed in jeopardy.
Advancing TrueMed’s Mission and Expanding Our Footprint
While counterfeit activity surged, 2025 was also a year when TrueMed’s momentum accelerated across the pharmaceutical industry. More companies adopted our AI authentication platform than ever before, expanding its use into additional product lines, new geographies, and new investigative teams.
The most recent use-case example comes from Alliance Pharmaceuticals Ltd., which demonstrated how new technology can deliver significant impact in the field, reducing observed counterfeits by 90% through dramatically improved speed and accuracy. TrueMed provided technology is set to transform field operations with its comprehensive capabilities, offering far more than a simple yes-or-no verification. The data, much more than yes or no data, collected in the field will become an invaluable resource, providing powerful insights and driving future activities in the field as well as in the packaging development.
This collective movement reflects a broader shift. Companies are no longer willing to rely solely on legacy security features that are slow to take in use and compromised quickly, or fully manual inspection which industry has been driving for years. They are embracing technology that can narrow hundreds of suspect units to a few meaningful targets in hours instead of weeks or months. They are investing in visibility, speed, and scalable defenses that match the pace of today’s counterfeiters.
Our work with top pharmaceutical partners reinforced this transition. A top ten pharma company selected TrueMed for advanced counterfeit investigations, underscoring how essential AI has become in protecting products already in market.
These advancements were not just announcements. They translated into measurable impact. Our case studies highlighted real-world results, from immediate clarity during investigations to dramatic reductions in counterfeit incidents after clients fully integrated TrueMed into their workflows.
Growth, Expansion, and New Capabilities
TrueMed continued to grow as a company throughout 2025. We expanded our physical presence, strengthened engineering and product teams, and increased our capacity to support deployments around the world. We welcomed new customers across diverse therapeutic categories, each bringing unique challenges and reinforcing the universal need for a modern, frictionless approach to product authentication.
This expansion has allowed us to support more product launches, broaden our global field coverage, and help companies protect existing inventory already distributed across multiple regions. Every engagement reaffirmed a core truth. Patients depend on the decisions we make and the technologies we deliver.
Trends That Defined 2025
Counterfeits grew significantly more sophisticated. Replicated batch numbers, cloned holograms, copied stickers, even compromised RFID tags, and increasingly accurate packaging became common. Traditional layered security models struggled to keep up.
Demand driven black markets continued to expand. GLP-1 treatments experienced unprecedented popularity, and with that popularity came a wave of fakes seeking to exploit vulnerable patients.
The counterfeit threat became more global and more coordinated. Incidents spread across Europe, Asia, the Middle East, Africa, and the Americas. Each region experienced unique patterns, but all required faster authentication and improved investigative workflows.
Pharmaceutical companies shifted toward proactive protection. Anti-counterfeit measures are now being positioned as a core element of patient safety, operational integrity, and regulatory readiness. This shift has been a major driver behind the rapid adoption of TrueMed.
Hope, Progress, and a Renewed Commitment
Despite the challenges, I am optimistic. The progress we saw in 2025 proved that innovation can move faster than the threat when it is backed by purpose, clarity and focus. Companies using TrueMed reduced risk, improved detection accuracy, and strengthened their ability to respond quickly.
The path forward requires vigilance and continual evolution. Counterfeiters will again adjust. Our responsibility is to stay ahead of those adjustments, expand our capabilities, and help every partner strengthen their protection strategy without disrupting manufacturing, packaging, or distribution.
Gratitude for the Team, Partners, Customers, and Patients
I want to express my sincere appreciation to the TrueMed team for their talent, ingenuity, and commitment to our mission. I am equally grateful to the customers and partners who trusted us to support their efforts to safeguard medicines already in the field.
Most importantly, I am grateful to the patients whose safety drives every innovation we introduce. You are the reason we push forward and the reason this work matters.
As we move into 2026, we carry the lessons of this year with focus and determination. TrueMed will continue to lead with purpose, innovation, and a clear commitment to restoring confidence in the authenticity of medicines around the world.